Maripau Wealth Management LLC acquired a new position in shares of Chemed Co. (NYSE:CHE - Free Report) in the fourth quarter, according to its most recent disclosure with the SEC. The firm acquired 676 shares of the company's stock, valued at approximately $358,000.
Several other hedge funds and other institutional investors also recently modified their holdings of CHE. FMR LLC increased its stake in Chemed by 23.8% in the 3rd quarter. FMR LLC now owns 238,616 shares of the company's stock valued at $143,401,000 after buying an additional 45,917 shares during the period. Principal Financial Group Inc. raised its stake in shares of Chemed by 114.1% during the 4th quarter. Principal Financial Group Inc. now owns 74,658 shares of the company's stock worth $39,554,000 after buying an additional 39,791 shares in the last quarter. Thrivent Financial for Lutherans grew its holdings in Chemed by 25.3% during the third quarter. Thrivent Financial for Lutherans now owns 146,017 shares of the company's stock worth $87,752,000 after acquiring an additional 29,445 shares during the period. Aureus Asset Management LLC raised its position in Chemed by 3,147.2% in the third quarter. Aureus Asset Management LLC now owns 29,939 shares of the company's stock worth $17,993,000 after acquiring an additional 29,017 shares in the last quarter. Finally, Boston Trust Walden Corp lifted its holdings in Chemed by 10.0% in the fourth quarter. Boston Trust Walden Corp now owns 242,172 shares of the company's stock valued at $128,303,000 after acquiring an additional 22,105 shares during the period. 95.85% of the stock is currently owned by hedge funds and other institutional investors.
Analyst Ratings Changes
CHE has been the subject of a number of research analyst reports. StockNews.com downgraded shares of Chemed from a "buy" rating to a "hold" rating in a report on Thursday, February 27th. Royal Bank of Canada dropped their target price on shares of Chemed from $697.00 to $633.00 and set an "outperform" rating for the company in a report on Tuesday, November 5th.
View Our Latest Report on CHE
Insider Buying and Selling at Chemed
In other news, VP Brian C. Judkins bought 145 shares of the business's stock in a transaction that occurred on Monday, December 30th. The stock was purchased at an average price of $519.50 per share, with a total value of $75,327.50. Following the purchase, the vice president now owns 1,678 shares of the company's stock, valued at $871,721. This trade represents a 9.46 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through this link. 3.32% of the stock is owned by insiders.
Chemed Stock Performance
NYSE CHE traded up $7.42 during trading hours on Wednesday, reaching $595.07. The company's stock had a trading volume of 106,099 shares, compared to its average volume of 98,535. The company's 50-day moving average is $549.47 and its two-hundred day moving average is $563.54. Chemed Co. has a fifty-two week low of $512.12 and a fifty-two week high of $654.62. The stock has a market cap of $8.96 billion, a PE ratio of 30.07, a PEG ratio of 2.15 and a beta of 0.48.
Chemed Announces Dividend
The business also recently announced a quarterly dividend, which will be paid on Friday, March 14th. Investors of record on Monday, February 24th will be paid a $0.50 dividend. This represents a $2.00 dividend on an annualized basis and a yield of 0.34%. The ex-dividend date is Monday, February 24th. Chemed's payout ratio is currently 10.05%.
About Chemed
(
Free Report)
Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers primarily in the United States. The company operates in VITAS and Roto-Rooter segments. It offers plumbing, drain cleaning, excavation, water restoration, and other related services to residential and commercial customers through company-owned branches, independent contractors, and franchisees.
Featured Articles
Before you consider Chemed, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Chemed wasn't on the list.
While Chemed currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
